Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Research output: Contribution to journalReviewResearchpeer-review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

    Research output: Contribution to journalReviewResearchpeer-review

  2. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Obesity as a Causal Risk Factor for Aortic Valve Stenosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jean-Charles Fruchart
  • Raul D Santos
  • Carlos Aguilar-Salinas
  • Masanori Aikawa
  • Khalid Al Rasadi
  • Pierre Amarenco
  • Philip J Barter
  • Richard Ceska
  • Alberto Corsini
  • Jean-Pierre Després
  • Patrick Duriez
  • Robert H Eckel
  • Marat V Ezhov
  • Michel Farnier
  • Henry N Ginsberg
  • Michel P Hermans
  • Shun Ishibashi
  • Fredrik Karpe
  • Tatsuhiko Kodama
  • Wolfgang Koenig
  • Michel Krempf
  • Soo Lim
  • Alberto J Lorenzatti
  • Ruth McPherson
  • Jesus Millan Nuñez-Cortes
  • Børge G Nordestgaard
  • Hisao Ogawa
  • Chris J Packard
  • Jorge Plutzky
  • Carlos I Ponte-Negretti
  • Aruna Pradhan
  • Kausik K Ray
  • Željko Reiner
  • Paul M Ridker
  • Massimiliano Ruscica
  • Shaukat Sadikot
  • Hitoshi Shimano
  • Piyamitr Sritara
  • Jane K Stock
  • Ta-Chen Su
  • Andrey V Susekov
  • André Tartar
  • Marja-Riitta Taskinen
  • Alexander Tenenbaum
  • Lale S Tokgözoğlu
  • Brian Tomlinson
  • Anne Tybjærg-Hansen
  • Paul Valensi
  • Michal Vrablík
  • Walter Wahli
View graph of relations

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.

Original languageEnglish
Article number71
JournalCardiovascular Diabetology
Volume18
Issue number1
ISSN1475-2840
DOIs
Publication statusPublished - 4 Jun 2019

ID: 58297148